![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANXA9 |
Gene summary for ANXA9 |
![]() |
Gene information | Species | Human | Gene symbol | ANXA9 | Gene ID | 8416 |
Gene name | annexin A9 | |
Gene Alias | ANX31 | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O76027 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8416 | ANXA9 | S43 | Human | Liver | Cirrhotic | 1.02e-04 | -1.86e-01 | -0.0187 |
8416 | ANXA9 | HCC1_Meng | Human | Liver | HCC | 1.84e-66 | 9.69e-03 | 0.0246 |
8416 | ANXA9 | HCC2_Meng | Human | Liver | HCC | 1.96e-03 | -1.25e-01 | 0.0107 |
8416 | ANXA9 | cirrhotic1 | Human | Liver | Cirrhotic | 5.21e-21 | 3.11e-01 | 0.0202 |
8416 | ANXA9 | cirrhotic2 | Human | Liver | Cirrhotic | 3.04e-14 | 2.53e-01 | 0.0201 |
8416 | ANXA9 | HCC2 | Human | Liver | HCC | 2.11e-02 | 2.48e+00 | 0.5341 |
8416 | ANXA9 | S015 | Human | Liver | HCC | 2.55e-04 | 5.32e-01 | 0.2375 |
8416 | ANXA9 | S016 | Human | Liver | HCC | 1.22e-02 | 2.59e-01 | 0.2243 |
8416 | ANXA9 | S029 | Human | Liver | HCC | 9.00e-03 | 4.95e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANXA9 | SNV | Missense_Mutation | rs140995793 | c.911N>G | p.Asp304Gly | p.D304G | O76027 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ANXA9 | SNV | Missense_Mutation | c.529N>A | p.Asp177Asn | p.D177N | O76027 | protein_coding | tolerated(0.29) | possibly_damaging(0.464) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ANXA9 | insertion | Frame_Shift_Ins | novel | c.845_846insAG | p.Leu283AlafsTer12 | p.L283Afs*12 | O76027 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
ANXA9 | insertion | Frame_Shift_Ins | novel | c.846_847insGTCATAGCTGAAGCCTTTTCACTCAT | p.Leu283ValfsTer20 | p.L283Vfs*20 | O76027 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
ANXA9 | SNV | Missense_Mutation | novel | c.421G>A | p.Ala141Thr | p.A141T | O76027 | protein_coding | deleterious(0.03) | possibly_damaging(0.572) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANXA9 | SNV | Missense_Mutation | c.376N>G | p.Leu126Val | p.L126V | O76027 | protein_coding | tolerated(0.07) | benign(0.266) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
ANXA9 | SNV | Missense_Mutation | rs112833633 | c.83N>T | p.Ala28Val | p.A28V | O76027 | protein_coding | tolerated(0.12) | probably_damaging(0.995) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANXA9 | SNV | Missense_Mutation | novel | c.158N>A | p.Ala53Asp | p.A53D | O76027 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANXA9 | SNV | Missense_Mutation | c.376C>A | p.Leu126Met | p.L126M | O76027 | protein_coding | tolerated(1) | benign(0.081) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ANXA9 | SNV | Missense_Mutation | novel | c.162T>G | p.Ile54Met | p.I54M | O76027 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |